Key Quantitative Figures
The data provided for the quarter is as follows:
- Number of Investor Complaints pending at the beginning of the quarter (01st April 2026): NIL
- Number of Investor Complaints received during the quarter (01st April 2026 to 30th June 2026): NIL
- Number of Investor Complaints disposed of during the quarter (01st April 2026 to 30th June 2026): NIL
- Number of Investor Complaints remaining unresolved at the end of the quarter (30th June 2026): NIL
Entities Involved & Regulatory References
The disclosure is addressed to:
- The Manager (Listing), BSE Limited, Mumbai
- The Manager (Listing), Ahmedabad Stock Exchange Ltd., Ahmedabad (CC)
The filing is made under SEBI LODR Reg. 13(3). The company's scrip codes are BSE: 531686 and ASE: 01636 (ADVIK LABO). The company's CIN is L74899HR1994PLC038300.
Dates and Signatory
The document is dated 10th July 2026. It was digitally signed by Pooja Chuni, Company Secretary, on 2026.07.10 at 17:21:32 +05'30'.
Financial Impact
No financial impact is mentioned or quantified in the disclosure. The filing is purely a compliance update on investor grievance status.
#Tags: #MPSPharmaa #SEBILODR #SEBIDisclosure #RegulatoryCompliance #Neutral